Monitoring trough plasma concentrations of mycophenolate mofetil in patients with uveitis

Journal of Clinical Pharmacy and Therapeutics

Volumn 29, Issue 1, 2004, Pages 53-58

  Llinares Tello, F ^a   Hernandez Prats C ^a   Munoz Ruiz C ^a   Selva Otaolaurruchi, J ^a   Ordovas Baines J P ^a  

^a Alicante General Hospital   (Spain)

Author keywords

Autoimmune; Mycophenolate mofetil; Mycophenolic acid; Therapeutic drug monitoring; Trough plasma concentration; Uveitis

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADOLESCENT; ADULT; AGED; AGITATION; ARTICLE; BEHCET DISEASE; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; EXCITEMENT; FEMALE; GRAVES DISEASE; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; MALE; PATIENT MONITORING; RISK ASSESSMENT; SCHOOL CHILD; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TOXICITY; TREATMENT FAILURE; UVEITIS;

ADULT; AGED; CHILD; DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; UVEITIS;

EID: 1342267644     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2003.00536.x     Document Type: Article

References (23)

1. Caspers-Velu LE (2001) Treatment of uveitis with immunosuppressives: antimetabolites and alkylating agents. Bulletin de la Societe Belge d'Ophtalmologie, 279, 59-69.
2. Eugui EM, Almquist S, Muller CD, Allison AC (1991) Lymphocyte selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotides depletion. Scandinavian Journal of Immunology, 33, 161-173.
3. Filler G, Hansen M, LeBlanc C et al. (2003) Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatric Nephrology, 18, 445-449.
4. Neumann I, Haidinger M, Jager H et al. (2003) Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients. Journal of the American Society of Nephrology, 14, 721-727.
5. Kilmartin DJ, Forrester JV, Dick AD (1998) Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet, 352, 35-36.
6. Larkin G, Lightman S (1999) Mycophenolate mofetil: a useful immunosuppressive in inflammatory eye disease. Ophthalmology, 106, 370-374.
7. Zierhut M, Stubiger N, Aboalchamat W, Landenberger H, Bialasiewicz AA, Engelmann K (2001) Immunosuppressive treatment with mycophenolate mofetil in the therapy of uveitis. Ophthalmology, 98, 647-651.
8. Greiner K, Varikkara M, Santiago C, Forrester JV (2002) Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis. Ophthalmology, 99, 691-694.
9. Baltatzis S, Tufail F, Yu EN, Vredeveld CM, Foster S (2003) Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology, 110, 1061-1065.
10. Nussenblatt RB, Palestine AG, Chan CC, Roberge F (1985) Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology, 92, 467-471.
11. Bullingham RES, Nicholls AJ, Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clinical Pharmacokinetics, 34, 429-455.
12. Shaw LM, Kaplan B, Kaufman D (1996) Toxic effects of immunosupressive drugs: mechanisms and strategies for controlling them. Clinical Chemistry, 42, 1316-1321.
13. Mourad M, Malaise J, Eddour DC et al. (2001) Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clinical Chemistry, 47, 88-94.
14. Hale MD, Nicholls AJ, Bullingham RE et al. (1998) The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clinical Pharmacology and Therapeutics, 64, 672-683.
15. Holt DW (2002) Monitoring mycophenolic acid. Annals of Clinical Biochemistry, 39, 173-183.
16. Weber LT, Shipkova M, Armstrong VW et al. (2002) Comparison of Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clinical Chemistry, 48, 517-525.
17. Langman LJ, LeGatt DF, Halloran PF, Yatscoff RW (1996) Pharmacodynamic assesment of mycophenolic acid induced immunosupression in renal transplant recipients. Transplantation, 62, 666-672.
18. Hubner GI, Eismann R, Sziegoleit W (2000) Relationship between mycophenolate mofetil side effects and mycophenolic acid plasma trough levels in renal transplant patients. Arzneimittel-Forschung, 50, 936-940.
19. Shaw LM, Nicholls A, Hale M et al. (1998) Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clinical Biochemistry, 31, 317-322.
20. Mourad M, Malaise J, Eddour DC et al. (2001) Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clinical Chemistry, 47, 1241-1248.
21. Filler G, Ehrich JH (1997) Mycophenolic mofetil for rescue therapy in acute renal transplant rejection in children should always be monitored by measurement of trough concentration. Nephrology, Dialysis, Transplantation, 12, 374-375.
22. Shaw LM, Kaplan B, DeNofrio D, Korecka M, Brayman KL (2000) Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Therapeutic Drug Monitoring, 22, 14-19.
23. Langmann LJ, LeGatt DF, Halloran PF, Yatscoff RW (1996) Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation, 62, 666-672.